(NASDAQ: ARWR) today announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference
(RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).
(NASDAQ: ARWR) has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference
therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency, the company said.
OliX Pharmaceuticals, a developer of RNA interference
therapeutics, has received the phase I clinical trial authorisation (CTA) for its anti-scar drug, OLX10010 from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), it was reported yesterday.
Their topics include direct and indirect methods of gene transfer in plants, RNA interference
and virus-induced gene silencing in plants, improving horticultural crops through biotechnological approaches, and biotechnological approaches for crop improvement in flowers and ornamental plants.
With the RNA Interference
or RNAi technology service offered by Altogen Labs it is possible to effectively regulate gene expression.
The discovery of RNA interference
earned two academics a Nobel Prize in 2006 and set off a scramble to create drugs that block disease-causing genes.
(RNAi) has emerged as a potent gene therapy strategy in the fight against cancer.
Craig Mello of the University of Massachusetts Medical School, who shared the 2006 Nobel Prize for medicine for a previous genetic discovery called RNA interference
, told the publication that Crispr is really a triumph of basic science and in many ways it's better than RNA interference
The topics include bioelectronic devices controlled by enzyme-based information processing systems, some experiments and models in molecular computing and robotics, in vivo information processing using RNA interference
, the logic of decision making in environmental bacteria, and qualitative and quantitative aspects of a model for processes inspired by the functioning of the living cell.
Summary: TEHRAN (FNA)- For the past decade, scientists have been pursuing cancer treatments based on RNA interference
- a phenomenon that offers a way to shut off malfunctioning genes with short snippets of RNA.
These small RNAs block gene expression through multiple RNA interference
(RNAi) pathways, including two newly discovered pathways in which small RNAs bind to Argonaut proteins or other forms of RNA present in the cell nucleus, such as long non-coding RNAs and pre-mRNA.